Literature DB >> 29048751

Severity strata for five patient-reported outcomes in adults with atopic dermatitis.

P P Vakharia1,2,3, R Chopra1,2,3, R Sacotte1,2,3, N Patel1,2,3, S Immaneni1,2,3, T White4, R Kantor1,2,3, D Y Hsu1,2,3, E L Simpson5, J I Silverberg1,4.   

Abstract

BACKGROUND: Several patient-reported outcomes have been used to assess the burden of atopic dermatitis (AD). Some are disease specific, such as the Patient-Oriented Eczema Measure (POEM), while others pertain to itch, for example the numerical rating scale (NRS)-itch, ItchyQoL and 5-D itch, or dermatological disease in general, for example the Dermatology Life Quality Index (DLQI). Development of severity strata is essential for proper interpretability of these assessments.
OBJECTIVES: To confirm previously developed strata for POEM, DLQI and raw ItchyQoL, and develop strata for the NRS-itch, mean ItchyQoL and 5-D itch scale for use in adults with AD.
METHODS: Self-administered questionnaires were completed by 210 adults with AD in a dermatology practice setting. Strata were selected using an anchoring approach based on patient-reported disease severity.
RESULTS: We confirmed the existing strata for POEM (mild 0-7, moderate 8-16, severe 17-28; κ = 0·440), DLQI (mild 0-5, moderate 6-10, severe 11-30; κ = 0·398) and NRS-itch (mild 0-3, moderate 4-6, severe 7-10; κ = 0·499). However, the preferred band for raw ItchyQoL was mild 22-58, moderate 59-74 and severe 75-110 (κ = 0·379) and for mean ItchyQoL, mild 1-2·9, moderate 3·0-3·9, severe 4·0-5·0 (κ = 0·374). The preferred band for 5-D itch scale was mild 0-11, moderate 12-17 and severe 18-25 (κ = 0·331).
CONCLUSIONS: Existing strata for POEM and DLQI performed well in adult AD. Previously reported strata for visual analogue scale-itch performed best for NRS-itch. We identified banding for the raw ItchyQoL for our AD population that varies slightly from the banding published for a more heterogeneous population. Finally, we proposed strata for mean ItchyQoL and 5-D itch scale in adult AD.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2018        PMID: 29048751      PMCID: PMC5906166          DOI: 10.1111/bjd.16078

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  29 in total

1.  Moderate correlation between quality of life and disease activity in adult patients with atopic dermatitis.

Authors:  I M Haeck; O ten Berge; S G A van Velsen; M S de Bruin-Weller; C A F M Bruijnzeel-Koomen; M J Knol
Journal:  J Eur Acad Dermatol Venereol       Date:  2011-03-24       Impact factor: 6.166

Review 2.  Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development.

Authors:  Catherine Copley-Merriman; Susan Zelt; Marci Clark; Ari Gnanasakthy
Journal:  Patient       Date:  2017-04       Impact factor: 3.883

Review 3.  The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results.

Authors:  M K A Basra; R Fenech; R M Gatt; M S Salek; A Y Finlay
Journal:  Br J Dermatol       Date:  2008-09-15       Impact factor: 9.302

4.  A pilot quality-of-life instrument for pruritus.

Authors:  Nisha S Desai; Gabriele B Poindexter; Yvette Miller Monthrope; Sandra E Bendeck; Robert A Swerlick; Suephy C Chen
Journal:  J Am Acad Dermatol       Date:  2008-06-11       Impact factor: 11.527

Review 5.  Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.

Authors:  P I Spuls; L A A Gerbens; E Simpson; C J Apfelbacher; J R Chalmers; K S Thomas; C A C Prinsen; L B von Kobyletzki; J A Singh; H C Williams; J Schmitt
Journal:  Br J Dermatol       Date:  2017-03-02       Impact factor: 9.302

6.  The 5-D itch scale: a new measure of pruritus.

Authors:  S Elman; L S Hynan; V Gabriel; M J Mayo
Journal:  Br J Dermatol       Date:  2009-12-01       Impact factor: 9.302

Review 7.  Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review.

Authors:  L A A Gerbens; J R Chalmers; N K Rogers; H Nankervis; P I Spuls
Journal:  Br J Dermatol       Date:  2016-07-28       Impact factor: 9.302

8.  Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus.

Authors:  Ngoc Quan Phan; Christine Blome; Fleur Fritz; Joachim Gerss; Adam Reich; Toshiya Ebata; Matthias Augustin; Jacek C Szepietowski; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2012-09       Impact factor: 4.437

9.  Validation of patient-reported global severity of atopic dermatitis in adults.

Authors:  P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; T White; R Kantor; D Y Hsu; J I Silverberg
Journal:  Allergy       Date:  2017-10-09       Impact factor: 13.146

Review 10.  What are the best outcome measurements for atopic eczema? A systematic review.

Authors:  Jochen Schmitt; Sinead Langan; Hywel C Williams
Journal:  J Allergy Clin Immunol       Date:  2007-10-01       Impact factor: 10.793

View more
  14 in total

1.  Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE).

Authors:  Jerry Bagel; Tien Q Nguyen; Hermenio Lima; Neal Jain; David M Pariser; Sylvia Hsu; Gil Yosipovitch; Haixin Zhang; Jingdong Chao; Shikha Bansal; Zhen Chen; Daniel Richman; Andrew Korotzer; Marius Ardeleanu
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-20

2.  Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis.

Authors:  Jonathan I Silverberg; Eric L Simpson; Mark Boguniewicz; Marjolein S De Bruin-Weller; Peter Foley; Yoko Kataoka; Gaëlle Bégo-Le-Bagousse; Zhen Chen; Brad Shumel; Jingdong Chao; Ana B Rossi
Journal:  Acta Derm Venereol       Date:  2021-11-10       Impact factor: 3.875

3.  The role of the nurse in the care and management of patients with atopic dermatitis.

Authors:  Harmieke van Os-Medendorp; Elfie Deprez; Nele Maes; Sheila Ryan; Karina Jackson; Tonya Winders; Linda De Raeve; Christa De Cuyper; Steven Ersser
Journal:  BMC Nurs       Date:  2020-11-04

4.  Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset.

Authors:  Lawrence F Eichenfield; April Armstrong; Emma Guttman-Yassky; Peter A Lio; Chi-Chang Chen; Dionne M Hines; Catherine B McGuiness; Sohini Ganguli; Dimittri Delevry; Debra Sierka; Usha G Mallya
Journal:  Dermatol Ther (Heidelb)       Date:  2022-05-11

5.  Release of cervical muscular tension improved severe pruritus in moderate-to-severe atopic dermatitis: A case series.

Authors:  Shusaku Hosono; Koji Fujita; Akimoto Nimura; Keiichi Akita
Journal:  JAAD Case Rep       Date:  2020-04-24

6.  Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.

Authors:  Lisa A Beck; Diamant Thaçi; Mette Deleuran; Andrew Blauvelt; Robert Bissonnette; Marjolein de Bruin-Weller; Michihiro Hide; Lawrence Sher; Iftikhar Hussain; Zhen Chen; Faisal A Khokhar; Bethany Beazley; Marcella Ruddy; Naimish Patel; Neil M H Graham; Marius Ardeleanu; Brad Shumel
Journal:  Am J Clin Dermatol       Date:  2020-08       Impact factor: 7.403

7.  Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice.

Authors:  A B Kimball; J J Crowley; K Papp; B Calimlim; Y Duan; A B Fleischer; J Sobell
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-03-01       Impact factor: 6.166

8.  What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.

Authors:  J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu
Journal:  Br J Dermatol       Date:  2020-09-21       Impact factor: 9.302

9.  Measurement properties of the product of investigator's global assessment and body surface area in children and adults with atopic dermatitis.

Authors:  J I Silverberg; D Lei; M Yousaf; S R Janmohamed; P P Vakharia; R Chopra; R Chavda; S Gabriel; K R Patel; V Singam; R Kantor; D Y Hsu
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-09-01       Impact factor: 6.166

10.  Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.

Authors:  Trisha Kaundinya; Uros Rakita; Armaan Guraya; Donna Maria Abboud; Emily Croce; Jacob P Thyssen; Andrew Alexis; Jonathan I Silverberg
Journal:  J Invest Dermatol       Date:  2021-08-02       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.